Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Arkea Bio Corp. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are distributed across 2 distinct examiners and 2 distinct art units. This indicates that each pending matter is being reviewed by a different individual in a separate specialized group within the USPTO's biotechnology and pharmaceutical divisions. The involvement of 2 distinct art units suggests that the pending matters may involve different technical sub-specialties.
The busiest examiner, FOLEY, SHANON A, is responsible for 1 pending office action. This means the workload is split, with each of the 2 distinct examiners handling a portion of the total pending workload. The presence of 2 distinct art units further confirms that the actions are subject to different supervisory guidelines. For the practitioner, this requires managing separate prosecution paths, as there is no concentration of examiners or art units for the 2 pending office actions. The strategy for each matter must be tailored to the specific examiner and art unit involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOLEY, SHANON A | 1 | 73.3% | +18.1% |
| JOHANSEN, PETER N. | 1 | 59.3% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18977008 | VACCINES COMPRISING METHANOBREVIBACTER GOTTSCHALKII | FOLEY, SHANON A | 264d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18977008 | VACCINES COMPRISING METHANOBREVIBACTER GOTTSCHALKII | FOLEY, SHANON A | 264d overdue |
| 18350526 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | JOHANSEN, PETER N. | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18977008 | VACCINES COMPRISING METHANOBREVIBACTER GOTTSCHALKII | FOLEY, SHANON A | 1671 | §103§112 | Non-Final OA | 264d overdue | Pending | Dec 11, 2024 |
| 18350526 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | JOHANSEN, PETER N. | 1644 | §112 | Final Rejection | — | Pending | Jul 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial